Catalog No. |
TD-HV493016 |
Species reactivity |
Human |
Applications |
Research Grade Biosimilar |
Host species |
Human |
Isotype |
IgG1-kappa |
Expression system |
Mammalian Cells |
Clonality |
Monoclonal |
Target |
CLEC12A, DCAL2, Dendritic cell-associated lectin 2, CLL-1, Myeloid inhibitory C-type lectin-like receptor, C-type lectin domain family 12 member A, CLL1, DCAL-2, C-type lectin-like molecule 1, MICL, CD371, T3E, T-cell surface antigen T3/Leu-4 epsilon chain, CD3e, CD3E, T-cell surface glycoprotein CD3 epsilon chain |
Endotoxin level |
Please contact the lab for this information. |
Purity |
>95% purity as determined by SDS-PAGE. |
Purification |
Protein A/G, purified from cell culture supernatant. |
Accession |
Q5QGZ9 & P07766 |
Form |
Liquid |
Storage buffer |
0.01M PBS,pH7.4. |
Stability and Storage |
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C. |
Alternate Names |
Bispecific,MCLA-117,PB9122,CAS:2044679-53-8 |
Background |
Tepoditamab (MCLA-117) is a bispecific monoclonal antibody that binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Among others, CLEC12A is a myeloid differentiation antigen. Tepoditamab (MCLA-117) kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research. |
Note |
For research use only. Not for use in clinical or therapeutic applications. |